TETRA DISCOVERY PARTNERS, INC.

Address

910 ROSEWOOD AVE SE
GRAND RAPIDS, MI, 49506-3362

http://www.tetradiscovery.com

Information

DUNS: 967529939
# of Employees: 6

Ownership Information

Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N

Award Charts




Award Listing

  1. Phosphodiesterase-4B (PDE4B) Inhibitors for Psychiatric Disease

    Amount: $991,394.00

    The prevalence of major depression is staggering with around of people experiencing depression at some point in their lives The market for antidepressant drugs is expected to grow at a CAGR of ...

    SBIRPhase II2016Department of Health and Human Services
  2. BPN14770 Safety and Cognitive Effect in Young and Elderly Subjects

    Amount: $2,055,899.00

    Project Abstract Tetra Discovery Partners is seeking Phase II SBIR funding for a multiple ascending dose human Phase clinical trial of BPN to evaluate safety tolerability pharmacokinetic and ...

    SBIRPhase II2016Department of Health and Human Services
  3. PDE4B Inhibitors for Treating Brain Injury

    Amount: $224,999.00

    DESCRIPTION provided by applicant This proposal will develop a new small molecule drug to be advanced into human clinical trials in the chronic post TBI patient who still has chronic cognitive im ...

    STTRPhase I2015Department of Health and Human Services
  4. PDE4D PET Ligand for Psychiatric Disease

    Amount: $346,237.00

    Tetra Discovery Partners is the recipient of an NIH Blueprint Neurotherapeutics Network award to develop phosphodiesterase D PDE D Negative Allosteric Modulators NAMs for treating memory loss in ...

    SBIRPhase I2015Department of Health and Human Services
  5. PDE4B Inhibitors For Treating Major Depression

    Amount: $3,003,708.00

    DESCRIPTION (provided by applicant): Tetra Discovery Partners proposes to develop a new treatment for major depressive disorder based on inhibition of phosphodiesterase 4B (PDE4B). Uniquely, the Tetra ...

    SBIRPhase II2013Department of Health and Human Services
  6. Phosphodiesterase Type IV (PDE4) Isoform Selective Allosteric Modulators For Psyc

    Amount: $698,827.00

    DESCRIPTION (provided by applicant): The broad goal of the SBIR proposal is to understand the pharmacology of phosphodiesterase 4 (PDE4) allosteric modulation in the CNS as it relates to psychiatric d ...

    SBIRPhase I2011Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government